Search
Ixabepilone
go.drugbank.com/drugs/DB04845ApprovedInvestigationalIxabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. … Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: Azaepothilone B, Aza-epothilone BCeliprolol
go.drugbank.com/drugs/DB04846ApprovedInvestigationalWithdrawnIt is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. … In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome.
Categories: Cytochrome P-450 Substrates, Adrenergic beta-2 Receptor AgonistsSynonyms: RS)-N'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylureaAZD0947
go.drugbank.com/drugs/DB04848ExperimentalAZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.
Biricodar
go.drugbank.com/drugs/DB04851InvestigationalThe pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).
Categories: P-glycoprotein inhibitors, Heterocyclic Compounds, 1-RingImplitapide
go.drugbank.com/drugs/DB04852InvestigationalImplitapide is a microsomal triglyceride transfer protein (MTP)-inhibitor.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingBinodenoson
go.drugbank.com/drugs/DB04853InvestigationalThis specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion … Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A<sub>2A</sub> receptor.
Categories: Heterocyclic Compounds, 2-RingSynonyms: 2-((Cyclohexylmethylene)hydrazino)adenosineBrasofensine
go.drugbank.com/drugs/DB04857ExperimentalPhase I/II trials for brasofensine have been completed in the U.K. In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230.
Tirapazamine
go.drugbank.com/drugs/DB04858InvestigationalThis activation is very useful as this hypoxic state is found in human solid tumors in a common phenomenon known as tumor hypoxia.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: 1,2,4-benzotriazin-3-amine, 1,4-dioxide, 3-Amino-1,2,4-benzotriazine 1,4-dioxideOmacetaxine mepesuccinate
go.drugbank.com/drugs/DB04865ApprovedInvestigationalWithdrawnOmacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies
Categories: Heterocyclic Compounds, 2-Ring, Heterocyclic Compounds with 4 or More RingsSynonyms: 1-[(1S,3aR,14bS)-2-Methoxy-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[a][1,3]dioxolo[4,5-H]pyrrolo[2,1-b][3]benzazepin-1-yl] 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate, CEPHALOTAXINE 4-METHYL (2R)-2-HYDROXY-2-(4-HYDROXY-4-METHYLPENTYL)BUTANEDIOATE (ESTER)Nilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigationalNilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). … ), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: TASIGNA® 150 MG CAPSULAS